ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Ultrasound-Mediated Biotransfection of Engineered Bone Marrow Mesenchymal Stem Cells in Treated Bone Defects through Intracellular Cavitation.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ultrasound-Mediated OFF-to-ON Switching of Bone Regeneration via a Bioorthogonal Cell-Capture Hydrogel, Enabling Spatiotemporal Control and Monitoring.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Biomaterial-assisted gene therapy for bone repair.Materials today. Bio · 2026Review
- Ultrasound-Mediated Biotransfection of Engineered Bone Marrow Mesenchymal Stem Cells in Treated Bone Defects through Intracellular Cavitation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The lack of stem cells and difficulty in osteogenic differentiation are the primary challenges to treating bone defects. Stem cell gene therapy can efficiently replenish the number of stem cells and facilitate bone differentiation, but its security and efficacy remain challenging. The traditional ultrasound-targeted microbubble destruction (UTMD) technology with extracellular cavitation for gene transfection is safe but inefficient. Consequently, gas vesicles extracted from Halobacterium NRC-1 are used as carriers, incorporating nuclear localization signal, polyethyleneimine, and plasmid bone morphogenetic protein 2 (pBMP2). Then followed by internalization into bone marrow mesenchymal stem cells (BMSCs) to produce engineered BMSCs, which exhibit significant capacity of lysosome escape and nuclear targeting. The permeability of the nuclear membrane is substantially enhanced by low-intensity pulsed ultrasound through intracellular cavitation, thereby increasing plasmid nuclear translocation efficiency and gene transfection efficiency by 284.7% and 131.6%, respectively, compared to conventional UTMD techniques. Besides, the expression of BMP2 is maintained for 21 days, promoting osteogenic differentiation of BMSCs and enhancing bone defect repair. In conclusion, this study provides a more secure, efficient, and regulated approach to BMSCs gene therapy for bone defects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.